Fast Facts: Biosimilars in Hematology and Oncology : Biologics and Biosimilars - Getting Decisions Right
Biologics have revolutionized – and are revolutionizing – the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days'exposure in Europe, shows that approved biosimilars can b...
| Autores principales: | , |
|---|---|
| Formato: | Libro |
| Publicado: |
S. Karger
2020
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | Biologics have revolutionized – and are revolutionizing – the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days'exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars – particularly in curative cancer treatment, where they are relatively recent therapeutic options.'Fast Facts: Biosimilars in Hematology and Oncology'provides a concise overview of emerging global practice in this fast-moving area together with practical information on adding biosimilars to a formulary and switching patients. |
|---|